Considering the crucial role of JAK2 in the pathogenesis of myeloproliferative illness, JAK2 inhibitors, ruxolitinib, and fedratinib were approved as new treatments for myelofibrosis and polycythemia vera. Here, JAK2 is linked to acquired polycythemia vera.